<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692391</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19050212</org_study_id>
    <nct_id>NCT02692391</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis</brief_title>
  <official_title>A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled pilot trial seeking to evaluate the&#xD;
      efficacy of rectal indomethacin in abrogating systemic inflammation and subsequently organ&#xD;
      failure and mortality in patients with AP and positive SIRS score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      AP is an inflammatory disease with a highly variable clinical course that is potentially&#xD;
      lethal. This disease is currently the leading cause of gastrointestinal-related hospital&#xD;
      admissions in the United States and continues to rise in incidence. The inciting event&#xD;
      leading to the development of AP is the premature activation of the digestive pro-enzyme&#xD;
      trypsinogen to trypsin within pancreatic acinar cells, resulting in pancreatic auto-digestion&#xD;
      and inflammation. Inflammation localized to the gland can subsequently progress to a systemic&#xD;
      inflammatory response affecting distant organs.&#xD;
&#xD;
      Studies have revealed a key role for phospholipase A2 in propagating this inflammatory&#xD;
      response by inducing the production of inflammatory mediators, including arachidonic acid&#xD;
      metabolites. Elevated levels of phospholipase A2 have been found in the serum of patients&#xD;
      with AP who develop severe complications, including pancreatic necrosis, shock, and OF. The&#xD;
      in vitro inhibition of phospholipase A2 using NSAIDs has been evaluated as a potential&#xD;
      treatment strategy for AP, with indomethacin shown to be the most potent inhibitor among 17&#xD;
      tested agents. NSAIDs also inhibit the interaction of neutrophils with endothelial cells,&#xD;
      thus preventing the accumulation of neutrophils at the site of injury.&#xD;
&#xD;
      In animal models of AP, NSAIDs have been shown to attenuate AP severity and improve survival.&#xD;
      Most human studies, however, have primarily assessed the role of NSAIDs in PEP prophylaxis. A&#xD;
      meta-analysis of 4 randomized, controlled studies evaluating this effect revealed a&#xD;
      protective role for these medications, and a recent multicenter, randomized controlled trial&#xD;
      found that administrating rectal indomethacin to patients at increased risk for PEP&#xD;
      significantly reduced the incidence and severity of pancreatitis. In 1985, a small randomized&#xD;
      controlled trial (n=30) of rectal indomethacin in patients with AP reported a significant&#xD;
      decrease in the duration of pain. This is the only study to date evaluating NSAIDs following&#xD;
      the onset of AP and did not evaluate systemic inflammation. The effect of rectal indomethacin&#xD;
      in mitigating disease progression in patients at risk for developing severe disease thus&#xD;
      remains to be evaluated.&#xD;
&#xD;
      SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical&#xD;
      parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension&#xD;
      and white blood count) that directly reflect the underlying inflammatory response. The&#xD;
      persistence of SIRS, defined by the presence of a SIRS score ≥2 at 48 hrs following&#xD;
      presentation, has been shown to be significantly associated with the development of OF,&#xD;
      pancreatic necrosis and death in patients with AP. Additionally, serum levels of CRP at 48&#xD;
      hours following admission have also been closely correlated with the development of OF.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      Our proposed randomized, double-blind, placebo-controlled pilot trial seeks to evaluate the&#xD;
      efficacy of rectal indomethacin in abrogating systemic inflammation in patients with acute&#xD;
      pancreatitis (AP) and systemic inflammatory response syndrome (SIRS).&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
      Our long-term goal is to alter the clinical course of AP in patients who are at high risk for&#xD;
      the development of organ failure (OF) and death. The objective of this randomized,&#xD;
      double-blind, placebo-controlled pilot trial is to evaluate the efficacy of rectal&#xD;
      indomethacin on attenuating systemic inflammation in patients with AP who also have SIRS. The&#xD;
      investigators hypothesize that the treatment of patients with AP and SIRS with therapeutic&#xD;
      doses of rectal indomethacin will mitigate the inflammatory response through the inhibition&#xD;
      of inflammatory mediators. The investigators will also test the hypothesis by enrolling 42&#xD;
      patients randomized to receive either rectal indomethacin or placebo for 48 hours and&#xD;
      pursuing the following specific aims:&#xD;
&#xD;
      Aim 1. Evaluate the effect of rectal indomethacin on systemic inflammation as measured by the&#xD;
      change in mean SIRS score and serum CRP levels following 48hrs of treatment in patients with&#xD;
      AP and SIRS; and&#xD;
&#xD;
      Aim 2. Evaluate the impact of rectal indomethacin on the development of OF and mortality.&#xD;
&#xD;
      Significance:&#xD;
&#xD;
      The proposed study will thus be the first attempt at evaluating the therapeutic role of&#xD;
      NSAIDs in patients with AP and SIRS who are at high risk for the development of OF and for&#xD;
      whom no effective pharmacological therapy is currently available. Pilot data generated will&#xD;
      serve as a platform for a larger scale study that will validate the efficacy of indomethacin&#xD;
      in the treatment of AP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 19, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic Inflammatory Response Syndrome (SIRS) Score</measure>
    <time_frame>The change in the SIRS score (48 hours - baseline)</time_frame>
    <description>SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-Reactive Protein (CRP) Levels.</measure>
    <time_frame>48 hours</time_frame>
    <description>CRP levels at 48 hours after enrollment minus CRP levels at enrollment (baseline). A negative number indicates a better outcome (less inflammation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Development of Organ Failure</measure>
    <time_frame>7 days</time_frame>
    <description>Including respiratory, renal and cardiovascular failures defined as modified Marshal score of equal and greater than 2. The minimum and maximum values in the modified Marshal score for each organ failure range from 0 to 4 with a higher value representing worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Enrolled subjects that died. A death indicates a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 doses, Q8hrs for a total period of 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin suppository</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
    <arm_group_label>Indomethacin suppository</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glycerin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients ages 18 or above admitted to UPMC with a diagnosis of AP based on at&#xD;
             least 2 of the following criteria:&#xD;
&#xD;
             (i) abdominal pain characteristic of AP (ii) serum amylase and/or lipase ≥ 3 times the&#xD;
             upper limit of normal (iii) characteristic findings of AP on abdominal CT scan will be&#xD;
             screened for study enrollment.&#xD;
&#xD;
          -  Patients with SIRS (≥ 2 of the following criteria: temperature &lt;36°C or &gt;38°C, heart&#xD;
             rate &gt;90/min, respiratory rate &gt;20/min OR PaCO2&lt;32 mmHg, WBC &lt;4,000/mm3, &gt;12,000/mm3&#xD;
             or &gt;10% bands) upon hospital admission or who develop SIRS during their first week of&#xD;
             hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of OF (shock defined by SBP&lt;90mmHg, PO2&lt;60mmHg on room air or need for&#xD;
             mechanical ventilation, Cr≥2mg/dL)&#xD;
&#xD;
          -  Presence of renal dysfunction (Cr&gt;1.5mg/dL)&#xD;
&#xD;
          -  Active peptic ulcer disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of daily NSAIDs within 1 week of presentation&#xD;
&#xD;
          -  Allergy to NSAIDs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgios I Papachristou, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sotoudehmanesh R, Eloubeidi MA, Asgari AA, Farsinejad M, Khatibian M. A randomized trial of rectal indomethacin and sublingual nitrates to prevent post-ERCP pancreatitis. Am J Gastroenterol. 2014 Jun;109(6):903-9. doi: 10.1038/ajg.2014.9. Epub 2014 Feb 11.</citation>
    <PMID>24513806</PMID>
  </results_reference>
  <results_reference>
    <citation>Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004 Jun;59(7):845-64. Review.</citation>
    <PMID>15173799</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <results_first_submitted>February 16, 2021</results_first_submitted>
  <results_first_submitted_qc>March 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2021</results_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>David Whitcomb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute pancreatitis</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Organ failure</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02692391/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02692391/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>6 doses, Q8hrs for a total period of 48 hours&#xD;
Placebo: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
        </group>
        <group group_id="P2">
          <title>Indomethacin Suppository</title>
          <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)&#xD;
Indomethacin: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>6 doses, Q8hrs for a total period of 48 hours&#xD;
Placebo: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
        </group>
        <group group_id="B2">
          <title>Indomethacin Suppository</title>
          <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)&#xD;
Indomethacin: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.5" lower_limit="35.6" upper_limit="63.1"/>
                    <measurement group_id="B2" value="50.8" lower_limit="42.2" upper_limit="61.1"/>
                    <measurement group_id="B3" value="50.8" lower_limit="37.2" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, continuous</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" lower_limit="26.9" upper_limit="37.4"/>
                    <measurement group_id="B2" value="27.8" lower_limit="23.1" upper_limit="35.2"/>
                    <measurement group_id="B3" value="30" lower_limit="24.3" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systemic Inflammatory Response Syndrome (SIRS) Score</title>
        <description>SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation).</description>
        <time_frame>The change in the SIRS score (48 hours - baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>6 doses, Q8hrs for a total period of 48 hours&#xD;
Placebo: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin Suppository</title>
            <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)&#xD;
Indomethacin: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Inflammatory Response Syndrome (SIRS) Score</title>
          <description>SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.81"/>
                    <measurement group_id="O2" value="-1" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-Reactive Protein (CRP) Levels.</title>
        <description>CRP levels at 48 hours after enrollment minus CRP levels at enrollment (baseline). A negative number indicates a better outcome (less inflammation).</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>6 doses, Q8hrs for a total period of 48 hours&#xD;
Placebo: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin Suppository</title>
            <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)&#xD;
Indomethacin: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein (CRP) Levels.</title>
          <description>CRP levels at 48 hours after enrollment minus CRP levels at enrollment (baseline). A negative number indicates a better outcome (less inflammation).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="8.73"/>
                    <measurement group_id="O2" value="-2.08" spread="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Development of Organ Failure</title>
        <description>Including respiratory, renal and cardiovascular failures defined as modified Marshal score of equal and greater than 2. The minimum and maximum values in the modified Marshal score for each organ failure range from 0 to 4 with a higher value representing worse outcomes.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>6 doses, Q8hrs for a total period of 48 hours&#xD;
Placebo: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin Suppository</title>
            <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)&#xD;
Indomethacin: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Development of Organ Failure</title>
          <description>Including respiratory, renal and cardiovascular failures defined as modified Marshal score of equal and greater than 2. The minimum and maximum values in the modified Marshal score for each organ failure range from 0 to 4 with a higher value representing worse outcomes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Enrolled subjects that died. A death indicates a worse outcome.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>6 doses, Q8hrs for a total period of 48 hours&#xD;
Placebo: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
          </group>
          <group group_id="O2">
            <title>Indomethacin Suppository</title>
            <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)&#xD;
Indomethacin: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Enrolled subjects that died. A death indicates a worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>6 doses, Q8hrs for a total period of 48 hours&#xD;
Placebo: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin</description>
        </group>
        <group group_id="E2">
          <title>Indomethacin Suppository</title>
          <description>Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)&#xD;
Indomethacin: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Georgios Papachristou, MD PhD</name_or_title>
      <organization>Ohio State University</organization>
      <phone>6142836255</phone>
      <email>georgios.papachristou@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

